Why is Cohance Life falling/rising?

As of 18-Sep, Cohance Lifesciences Ltd is experiencing a decline in its stock price, currently at 914.15, reflecting a decrease of 52.85 points or 5.47%. The stock has underperformed its sector by 6.52% today and has been on a downward trend for the last two days, accumulating a total loss of 7.62%. It opened with a significant gap down of 4.14% and reached an intraday low of 888.85, indicating strong selling pressure. Over the past week, the stock has fallen by 8.40%, while its year-to-date performance shows a decline of 19.34%. Despite having high management efficiency with a return on equity (ROE) of 24.14% and a low debt-to-equity ratio, the company faces challenges such as poor long-term growth, flat quarterly results, and a high valuation compared to peers, which contribute to the negative sentiment surrounding the stock.
Broader market context indicates that while the Sensex has gained 1.80% over the past week, Cohance Lifesciences has significantly lagged behind, highlighting its underperformance in the market. The stock's return over the last year is notably worse than the broader market, with a decline of 20.69% compared to the BSE500's negative return of 1.96%. Additionally, the increasing proportion of pledged promoter shares adds to the downward pressure on the stock, particularly in a falling market. This combination of factors, including declining investor participation and unfavorable financial metrics, suggests a challenging environment for Cohance Lifesciences Ltd, leading to its current price decline.